Simultaneous pancreas-kidney (SPK) transplantation is an important treatment option for patients with type 1 diabetes (T1D) and end-stage renal disease (ESRD). Due to complications, in up to 10% of patients, allograft pancreatectomy is necessary shortly after transplantation. Usually the donor pancreas is discarded. Here, we report on a novel procedure to rescue endocrine tissue after allograft pancreatectomy. A 39-year-old woman with T1D and ESRD who had undergone SPK transplantation required emergency allograft pancreatectomy due to bleeding at the vascular anastomosis. Islets were isolated from the removed pancreas allograft, and almost 480 000 islet equivalents were infused into the portal vein. The patient recovered fully. After 3 months, near-normal mixed meal test (fasting glucose 7.0 mmol/L, 2-hour glucose 7.5 mmol/L, maximal stimulated C-peptide 3.25 nmol/L, without insulin use in the preceding 36 hours) was achieved. Glycated hemoglobin while taking a low dose of longacting insulin was 32.7 mmol/mol hemoglobin (5.3%). When a donor pancreas is lost after transplantation, rescue β cell therapy by islet alloautotransplantation enables optimal use of scarce donor pancreata to optimize glycemic control without additional HLA alloantigen exposure.
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| CASE DESCRIPTION
A 39-year-old woman was admitted for SPK transplantation. She had been diagnosed with T1D at the age of 3 years. She was blind due to diabetic retinopathy, despite laser coagulation treatment, and had ESRD due to diabetic nephropathy, for which she required hemodialysis since 4 years. There were no other relevant medical problems. 
| RESULTS
After the islet transplantation, the patient required intravenous insulin up to a dosage of 30 IU daily while aiming for blood glucose concentrations between 4 and 7 mmol/L. C-peptide measurements demonstrated endogenous insulin production during this period (Table 1) .Twenty days after islet transplantation, she was switched from intravenous insulin to multiple daily injections (long-acting insulin glargine and prandial insulin aspart). The insulin requirement increased to a maximum of 40 to 50 IU daily for adequate glycemic control (glucose 5 to 9 mmol/L, 
| DISCUSSION
We report a successful islet transplantation with islets isolated from a pancreas allograft that had been removed in an emergency setting due to life-threatening bleeding from a mycotic aneurysm of the Ygraft. Subsequent islet isolation and transplantation resulted in excellent endogenous insulin production, with low insulin requirement and a near-normal glucose tolerance and HbA 1c . This corresponded with a high C-peptide response to a mixed meal tolerance test. We term this procedure "islet alloautotransplantation" to indicate the transplantation of islets isolated from an allogeneic donor pancreas that was transplanted previously into the same recipient as the islets.
Allogeneic pancreas transplantation combined with kidney transplantation is considered standard of care for patients with T1D and ESRD, but it is still a procedure that is characterized by considerable complications. These complications include abdominal infections, thrombosis, bleeding, and transplant pancreatitis. Up to 10%
of transplanted patients require allograft pancreatectomy. 3, 4 In light of the shortage of donor organs, 13,14 discarding a donor pancreas after transplantectomy could be considered a waste of resources if islets from this pancreas are still viable and thus useful for the patient. Therefore, using this otherwise discarded pancreas provides an opportunity to rescue the endocrine tissue. Islet transplantation has important beneficial effects. By partial or sometimes even full restoration of endogenous insulin production, it alleviates hypoglycemia burden and improves quality of life. [15] [16] [17] Endogenous insulin production has also been shown to be associated with prevention or stabilization of diabetes-related complications, even if insulin independence is not achieved. 18, 19 Therefore, restoration of endogenous insulin production is an important goal of treatment. With islet alloautotransplantation, the advantages of endogenous insulin production are achieved shortly after allograft pancreatectomy, avoiding additional donor HLA exposure, in case the patient would have been waitlisted and transplanted again, and making optimal use of donor organ resources. Therefore, this procedure has important implications both for the individual patient with diabetes and for transplantation health care in general.
The procedure differs in several aspects from regular islet autotransplantation or allotransplantation. Allograft pancreatectomy is often performed in an acute clinical setting with challenging logistics for back table flushing of the allograft with preservation solution and subsequent islet isolation compared with a planned autologous pancreatectomy and islet isolation. Therefore, optimal coordination between the surgical team and islet isolation team is critical to the success of this complicated procedure. In addition, the donor 
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pancreas is often damaged (ie, by infection, thrombosis, fibrosis, or inflammation), and the presence of peripancreatic fluid collections, which are often present after pancreas transplantation, 1 is an important risk for contamination of the islet preparation after isolation.
To reduce the risk of infection after islet infusion, a strategy to use antibiotics in all isolation fluids, to infuse islets as quickly as possible, and to apply antibiotic coverage against enteric microorganisms (preferably based on the antibiogram of previous cultures) is appropriate. Furthermore, the proinflammatory state of the patient can increase the risk of both bleeding and thrombosis. 20 Therefore, we used a lower dose of intraportal heparin during the islet transplantation procedure. The transplantation team should weigh the benefits of restoration of endogenous insulin production against the risks of infection and thrombotic or bleeding complications due to the islet infusion.
In conclusion, islet alloautotransplantation is a novel treatment option that offers patients who have undergone pancreas transplantation but require transplant pancreatectomy a second chance at endogenous insulin production with its associated benefits. With this procedure, a repeated pancreas or islet transplantation and exposure to additional allogeneic HLA antigens may be avoided.
